HOME MONITORING PRODUCTS

AirSonea®

The convenient and easy-to-use AirSonea device connects via Bluetooth® with a sophisticated smartphone app to detect and measure wheeze.

The app features asthma management diary features; medication usage and reminders, and symptoms and triggers to help asthma sufferers gain a better understanding of how their condition affects them and importantly, help them better adhere to their treatment plans. Further features including weather conditions and pollen count are planned.

SonoSentry™

SonoSentry is the first over-the-counter wheeze detection device cleared by the FDA. It is a stand alone device with on board computation. Currently USB connected to PC, but data can be uploaded to cloud via web portal.

Wholter™

Symptoms of asthma, including wheeze, are generally worse at night and early morning. The FDA cleared Wholter is designed for 8-24 hour home ambulatory recording (nocturnal wheeze, cough). This option of monitoring asthma patients and collecting data for a period of time in the patient’s own home is important for both doctor in their design of treatment plans and patient, particularly parents of children with asthma. Respiri is currently exploring an upgrade to wireless capability and app function.

CLINICAL/HOSPITAL MONITORING (PULMOTRACK)

PulmoTrack™ Computerised Wheeze Detection

PulmoTrack is Respiri’s foundation product, designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute, sever asthma in the ER and ICU, and for Pediatric Pulmonary Function Testing and Sleep Labs. The PulmoTrack module has a wireless connection to a PC. PulmoTrack is FDA cleared.

In a recent study conducted at the Department of Neonatology, Charité University Medical Centre, Berlin, Germany, wheezes were detected using the PulmoTrack® Model 2020. “….an instrument developed for continuous tracking and recording of breathing sounds and the detection of wheezing. Computerised wheeze detection is feasible during the first year of life. This method is more objective and can be more readily standardised than subjective auscultation, providing quantitative and noninvasive information about the extent of wheezing”.

Puder et al BMC Paediatrics 2014

ASX ANNOUNCEMENTS

Respiri remains on track for commercialisation - August 9, 2017Read now